EMA Accepts Daiichi Sankyo's Application for Enhertu in HER2-Positive Breast Cancer

NEW YORK – Daiichi Sankyo said on Monday that the European Medicines Agency has accepted its marketing authorization application for trastuzumab deruxtecan (Daiichi Sankyo's Enhertu, DS-8201) for previously-treated HER2-positive breast cancer. The application has also been granted accelerated assessment by EMA's Committee for Medicinal Products for Human Use.